New Hepatitis C Treatment

Published Online: Friday, February 24, 2012
Follow Pharmacy_Times:
The standard treatment for hepatitis C, interferon and ribavirin, cures just 45% of those who receive it. There are now several dozen new drugs for the disease under development, and 2 were approved by the FDA in 2011: telaprevir and boceprevir. The new drugs, which directly attack the virus that causes hepatitis C with minimal impact on the human host, have raised hopes of shorter treatment times and higher cure rates. Researchers are also looking at ways of tailoring treatment to individual patients based on genetic testing.
 
To learn more, check out this video:

Related Articles
Aaron Steffenhagen, PharmD, BCPS, a clinical pharmacy manager at the University of Wisconsin Hospital, discusses what areas pharmacists should focus on during acute stroke codes.
Aaron Steffenhagen, PharmD, BCPS, a clinical pharmacy manager at the University of Wisconsin Hospital, discusses a pharmacist's door-to-door discharge role when managing an ischemic stroke patient.
Aaron Steffenhagen, PharmD, BCPS, a clinical pharmacy manager at the University of Wisconsin Hospital, discusses how pharmacists can enhance stroke care.
The FDA today approved ombitasvir, paritaprevir, and ritonavir tablets copackaged with dasabuvir tablets to treat individuals with chronic hepatitis C virus genotype 1 infection, including patients with cirrhosis.
Latest Issues
$auto_registration$